阿尔茨海默病的重复性行为:系统性审查和元分析
Clément Polin1,2, Thibaut Gellé2, Emilie Auditeau2
1Centre Mémoire de Ressources et de Recherche du Limousin, Pôle Universitaire de Psychiatrie de l'Adulte, de l'Agé et d'Addictologie, Centre Hospitalier Esquirol, Limoges, France.
Journal of Alzheimer's disease : JAD
|October 2, 2023
概括
重复性行为 (RBs) 影响66.3%的阿尔茨海默病 (AD) 患者,与记忆或执行功能障碍有关. 了解这些RB对于改善患者管理至关重要.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 精神病学是一个精神病学.
背景情况:
- 重复性行为 (RBs) 是阿尔茨海默氏症 (AD) 已知但未被充分研究的症状.
- 现有的文献缺乏关于阿尔茨海默病患者RB的频率,性质和认知基础的全面审查.
结论:
- 两种主要机制是阿尔茨海默病中RB的基础:情节性记忆障碍 (轻度阶段) 和执行功能障碍 (后期阶段).
- 进一步的研究是必不可少的,以提高对阿尔茨海默病中RB的理解和管理策略.
更多相关视频
相关概念视频
01:26Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
01:22Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212